BRAF and melanoma: The BRAF V600 mutation is the only validated predictive biomarker for patients with melanoma, which is highly predictive for response to BRAF inhibitors with a low rate of primary resistance [11], resulting in longer median survival than those patients with wild-type BRAF melanoma.